Results 161 to 170 of about 4,640 (210)

Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial

Blood
Background: Patients newly diagnosed with multiple myeloma (NDMM) harboring high-risk (HR) factors typically have a poor prognosis. According to the mSMART 3.0 criteria, high-risk factors for MM include del(17p), t (4; 14), t (14; 16), del 17p, p53
Xiao-Qin Chen, Yun Wang, Zhi-Jian Liang, Wei-Da Wang, Hua Wang, Bingyi Wu, Yang Liang, Zhong-Jun Xia   +7 more
semanticscholar   +1 more source

SH2B3 expression predicts selinexor sensitivity in acute myeloid leukemia

Blood
Background Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy. Despite recent therapeutic advances, patients continue to experience poor outcomes and high rates of relapse, highlighting the need for novel targeted therapies ...
Shi-Yuan Zhang, Long-Long Liu, Bin Xu, X. Tong, A. Fu, Shuai-Xi Su, Yi Zhu, Zhuoxin Wen, Jia Wei, Donghua Zhang   +9 more
semanticscholar   +1 more source

Safety assessment of selinexor: a real-world pharmacovigilance study.

Expert Opinion on Drug Safety
BACKGROUND Selinexor is approved for the treatment of relapsed or refractory multiple myeloma. However, a comprehensive understanding of adverse events associated with selinexor is lacking. METHODS Clinical trials of selinexor in patients with multiple
Wei Zhang, Kai Tao, Bin Zeng, Ling-Hui Deng, P. Lu, Ting Niu, Shi Qiu, Lu Yang   +7 more
semanticscholar   +1 more source

Selinexor

Reactions Weekly, 2020
openaire   +2 more sources

Upregulation of BCMA expression by selinexor

Blood
Abstract Introduction Selinexor is a first-in-class, selective inhibitor of nuclear export that targets exportin 1 (XPO1), a key nuclear export protein involved in the transport of tumor suppressor proteins and oncogenic factors from the nucleus to the cytoplasm.
Christina Verbruggen, Umair Munawar, Seungbin Han, Julia Mersi, Emma Besant, Shilpa Kurian, Silvia Nerreter, Nina Rein, Johanna Lehmann, Max Koeppel, Hermann Einsele, Leo Rasche, Johannes Waldschmidt, K. Martin Kortüm   +13 more
openaire   +1 more source

Efficacy and safety of selinexor in combination with CD19/CD22 bispecific chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory diffuse large B-cell lymphoma: A single-center, retrospective, real-world study

Blood
Although anti-CD19 CAR-T cell therapy demonstrates high response rates in Diffuse Large B-Cell Lymphoma (DLBCL), therapeutic resistance remains a challenge in certain patient subsets due to functional impairments in CAR-T cells and an ...
He Wang, Xin-Di Liu, Yuan Liang, Liang Wang, J. Cong   +4 more
semanticscholar   +1 more source

Selinexor

Reactions Weekly, 2021
openaire   +1 more source

Selinexor-based non-intensive chemotherapy regimens adjusted according to early responses achieve high early remission in newly diagnosed AML or MDS

Blood
Background Some newly diagnosed (ND) acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) patients (pts) are ineligible for or unwilling to receive intensive chemotherapy.
Shi-Yuan Zhang, Shuai-Xi Su, Bin Xu, X. Tong, Yi Zhu, A. Fu, Zhuoxin Wen, Zhiqiong Wang, Jia Wei, Donghua Zhang   +9 more
semanticscholar   +1 more source

Synergistic effects of MALT1 inhibitor and selinexor on Acute Myeloid Leukemia cells and the underlying mechanisms

Blood
Background: Current treatment of acute myeloid leukemia (AML) is primarily based on combination chemotherapy, which has certain limitations. Therefore, the development of novel targeted therapeutics is urgently needed for the treatment of AML ...
Li-Yuan Li, Wei-Guang Cui, Nan Zhou, Zhen-Zhen Wang   +3 more
semanticscholar   +1 more source

Osimertinib synergizes selinexor on anti-tumor effect by targeting c-MYC in T-cell acute lymphoblastic leukemia

Blood
Background Adult T-cell acute lymphoblastic leukemia (T-ALL), a hematological malignancy derived from T lymphocyte hematopoietic stem cells, is highly aggressive and has a poor prognosis, with a 5-year survival rate of less than 40% under current ...
Rushuang Xu, Dong-Feng Zeng, Xi Li
semanticscholar   +1 more source